Regenerative medicine scientists at IDIBELL in collaboration with partners at Ulm University (Germany) have demonstrated that inhibition of Cdc42 with CASIN can pharmacologically extend lifespan.
This 33rd edition, now virtual, has been organized by the professional team of the Cancer Epidemiology Research Program (IDIBELL-ICO) and by the IPVC.
A team from IDIBELL and ICO, using a mouse orthotopic model, conducted a real-time personalized oncology study to test the best therapeutic option to treat a type of relapse sarcoma.
Designed a new and user-friendly model to predict the life expectancy of a severe neurodegenerative disease
Researchers from IDIBELL, the University of Göttingen and the University of Münster, designed six tables, using data available at the time of diagnosis, where easily extrapolate patient’s life expectancy.
Dr. Bárbara Rivera receives the support of the Mutua Madrileña Foundation to investigate a rare childhood disease
The grant will go thyroid abnormalities research in rare childhood diseases.
A study proposes a new approach for the identification of a syndrome of predisposition to childhood cancer
Patients with this syndrome have more mutations in the microsatellite regions of the genome. The detection of these mutations improves the diagnosis and therapeutic management of patients.